Literature DB >> 19133779

Antiprotealide is a natural product.

Rama Rao Manam1, Venkat R Macherla, Ginger Tsueng, Chris W Dring, Jeffrey Weiss, Saskia T C Neuteboom, Kin S Lam, Barbara C Potts.   

Abstract

Large-scale fermentation of the marine actinomycete Salinispora tropica for production of salinosporamide A (NPI-0052; 1) clinical trials materials provided crude extracts containing minor secondary metabolites, including salinosporamide B (2) and a new congener, 3. Spectroscopic characterization revealed that 3 is identical to antiprotealide, a molecular hybrid of 20S proteasome inhibitors 1 and omuralide (4) not previously described as a natural product. Analysis of crude extracts from shake flask cultures of three wild-type S. tropica strains confirmed the production of antiprotealide at 1.1, 0.8, and 3.0 mg/L. Thus, antiprotealide is a natural product metabolite of S. tropica.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19133779     DOI： 10.1021/np800578e

Source DB:  PubMed          Journal:  J Nat Prod        ISSN： 0163-3864            Impact factor:   4.050


  11 in total

Review 1.  Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.

Authors:  Tobias A M Gulder; Bradley S Moore
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-03       Impact factor: 15.336

2.  Bioinspired total synthesis and human proteasome inhibitory activity of (-)-salinosporamide A, (-)-homosalinosporamide A, and derivatives obtained via organonucleophile promoted bis-cyclizations.

Authors:  Henry Nguyen; Gil Ma; Tatiana Gladysheva; Trisha Fremgen; Daniel Romo
Journal:  J Org Chem       Date:  2010-11-03       Impact factor: 4.354

Review 3.  The marine actinomycete genus Salinispora: a model organism for secondary metabolite discovery.

Authors:  Paul R Jensen; Bradley S Moore; William Fenical
Journal:  Nat Prod Rep       Date:  2015-05       Impact factor: 13.423

Review 4.  Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Authors:  B C Potts; M X Albitar; K C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; A Younes; M A Palladino
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

5.  Engineering fluorometabolite production: fluorinase expression in Salinispora tropica Yields Fluorosalinosporamide.

Authors:  Alessandra S Eustáquio; David O'Hagan; Bradley S Moore
Journal:  J Nat Prod       Date:  2010-03-26       Impact factor: 4.050

Review 6.  Antitumor compounds from marine actinomycetes.

Authors:  Carlos Olano; Carmen Méndez; José A Salas
Journal:  Mar Drugs       Date:  2009-06-11       Impact factor: 5.118

Review 7.  Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.

Authors:  Barbara C Potts; Kin S Lam
Journal:  Mar Drugs       Date:  2010-03-25       Impact factor: 5.118

8.  Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.

Authors:  Markus Nett; Tobias A M Gulder; Andrew J Kale; Chambers C Hughes; Bradley S Moore
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

9.  Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.

Authors:  Grace E Hubbell; Jetze J Tepe
Journal:  RSC Chem Biol       Date:  2020-09-16

10.  Enzymatic assembly of the salinosporamide γ-lactam-β-lactone anticancer warhead.

Authors:  Katherine D Bauman; Vikram V Shende; Percival Yang-Ting Chen; Daniela B B Trivella; Tobias A M Gulder; Sreekumar Vellalath; Daniel Romo; Bradley S Moore
Journal:  Nat Chem Biol       Date:  2022-03-21       Impact factor: 16.174
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.